Nasus Pharma (NSRX) FDA Approvals $2.91 -0.07 (-2.35%) Closing price 04:10 PM EasternExtended Trading$2.94 +0.03 (+1.03%) As of 04:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartEarningsFDA EventsNews and TrendsSEC Filings Nasus Pharma's Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Nasus Pharma (NSRX). Over the past two years, Nasus Pharma has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as NS002. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. NS002 FDA Regulatory Events NS002 is a drug developed by Nasus Pharma for the following indication: treatment of anaphylaxis. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Abstract - November 10,2026Abstract Drug: NS002Announced Date: November 10, 2026Indication: treatment of anaphylaxisAnnouncementNasus Pharma Ltd. announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology (“ACAAI”) 2026 Annual Scientific Meeting, to be held in Phoenix, AZ November 12-16, 2026.Read Announcement Nasus Pharma FDA Events - Frequently Asked Questions Has Nasus Pharma received FDA approval? As of now, Nasus Pharma (NSRX) has not received any FDA approvals for its therapy in the last two years. What drugs has Nasus Pharma submitted to the FDA? In the past two years, Nasus Pharma (NSRX) has reported FDA regulatory activity for NS002. What is the most recent FDA event for Nasus Pharma? The most recent FDA-related event for Nasus Pharma occurred on November 10, 2026, involving NS002. The update was categorized as "Abstract," with the company reporting: "Nasus Pharma Ltd. announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology (“ACAAI”) 2026 Annual Scientific Meeting, to be held in Phoenix, AZ November 12-16, 2026." What conditions do Nasus Pharma's current drugs treat? Currently, Nasus Pharma has one therapy (NS002) targeting the following condition: treatment of anaphylaxis. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events BridgeBio Pharma FDA EventsGuardant Health FDA EventsPrima BioMed FDA EventsNeonc Technologies FDA EventsVanda Pharmaceuticals FDA EventsBlack Diamond Therapeutics FDA EventsBeam Therapeutics FDA EventsBioVie FDA EventsBiomea Fusion FDA EventsCingulate FDA EventsCity Therapeutics FDA EventsFate Therapeutics FDA EventsKailera Therapeutics FDA EventsLipocine FDA EventsLantern Pharma FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Journey Medical FDA Events Zentalis Pharmaceuticals FDA Events PolyPid FDA Events Minerva Neurosciences FDA Events Immunic FDA Events NRx Pharmaceuticals FDA Events Milestone Pharmaceuticals FDA Events Polaryx Therapeutics FDA Events vTv Therapeutics FDA Events Cumberland Pharmaceuticals FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NYSEAMERICAN:NSRX last updated on 11/10/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | SponsoredDon't lose access to thisIan Cooper is giving away his guide, The Simple Path To Success With Options, before it moves behind a paywall...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nasus Pharma Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nasus Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Abstract - November 10,2026Abstract Drug: NS002Announced Date: November 10, 2026Indication: treatment of anaphylaxisAnnouncementNasus Pharma Ltd. announced that abstracts supporting NS002, its investigational intranasal epinephrine powder for the treatment of anaphylaxis, have been accepted for presentation at the upcoming the American College of Allergy, Asthma & Immunology (“ACAAI”) 2026 Annual Scientific Meeting, to be held in Phoenix, AZ November 12-16, 2026.Read Announcement
Free NSRX Stock Alerts